ADAM10 and breast cancer: However, using the transcriptomic and proteomic datasets from the above-mentioned breast cancer patient cohort, it was found that the expression levels of ADAM10/17 were comparable in breast cancers with low and high sICOSL levels (Fig. 4C), suggesting that ADAM10/17 is not a key regulator of sICOSL levels in breast cancer.